Saliva as a propitious diagnostic biofluid, biomarker, and bodies first line of defense against COVID-19: A review

Akshay Langalia¹, Nidhi Sinha², Viral Thakker³, Aarshvi Shah¹, Jinali Shah¹, Bijay Singh⁴

¹Departments of Conservative Dentistry and Endodontics and ³Periodontics, AMC Dental College and Hospital, Ahmedabad, Gujarat, ²Department of Conservative Dentistry and Endodontics, Pacific Dental College and Hospital, Udaipur, Rajasthan, ⁴Department of Prosthodontics, Pacific Dental College and Hospital, Udaipur, Rajasthan, India

ABSTRACT

This review aims to recognize the role of saliva not just as a transmitting agent of COVID 19, but also comprehend its role in the diagnosis, and as a biomarker. A systematic literature search was performed in the PubMed database and eligible studies were included if they addressed the key issues i.e. saliva as a diagnostic aid. As of January 10, 2021, a total of 309 articles across the PubMed database were identified of which 28 studies met the inclusion criteria. They were carefully examined for the type of study, sample size, parameters used, sample collection technique, and conclusions drawn. Diagnostic properties of saliva, the role of ACE 2 receptors, antibody formation ability, and antiviral characteristics were also explored. Comparisons among methods of sample collection like nasopharyngeal swabs and oropharyngeal swabs to saliva were also investigated. The observations and important deductions among the different studies were compared. Results indicated that saliva could be a reliable and financially viable option in both testing viral titers as well as marking for bio analytes due to its propitious specificity and sensitivity results reported in most of the studies. However, the inferences drawn from many of these studies should be interpreted with caution due to small sample sizes, inadequate detailing on the sample handling, laboratory processing, and rush in Corona-related publication. Scientific research with larger sample sizes, in diverse populations and age groups, at different phases of disease progression of COVID-19 are essential to reach any conclusion regarding its multi-facet use in the future.

Keywords: Antibodies in SARS-CoV-2, saliva and COVID-19, saliva as a diagnostic tool, SARS-CoV-2

Introduction

Coronoviridae is a large, enveloped, single-stranded RNA virus.[1] The term corona (crown in Latin) means a spherical form with surface projections.[2] Coronavirus is divided basically into four groups Alpha, Beta, Gamma, and Delta. Alpha and Beta forms infect the respiratory tract, gastrointestinal tract, the central nervous system in mammals whereas Gamma and Delta forms mostly infect birds.[3] The Beta form appears to have originated from live animals and the seafood market in China which could have harbored the first virus found in animals. This was later transmitted to humans and started evolving faster in humans. Bats have the same genomic sequence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) which could be the accountable cause for COVID-19.[2] In 1030% patients, it leads to severe upper respiratory tract illness including SARS and Middle East Respiratory Syndrome (MERS).[3,4] SARS-CoV-2 may also cause severe lower respiratory tract infection and ACE-2 receptors are its predominant binding proteins.[5] The virus can survive on various surfaces when it gets favorable humidity and temperature [Table 1].[4,5] It can even from live animals and the seafood market in China which could have harbored the first virus found in animals. This was later transmitted to humans and started evolving faster in humans. Bats have the same genomic sequence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) which could be the accountable cause for COVID-19.[2] In 1030% patients, it leads to severe upper respiratory tract illness including SARS and Middle East Respiratory Syndrome (MERS).[3,4] SARS-CoV-2 may also cause severe lower respiratory tract infection and ACE-2 receptors are its predominant binding proteins.[5] The virus can survive on various surfaces when it gets favorable humidity and temperature [Table 1].[4,5] It can even
endure a temperature of -80°C but can be inactivated by exposure to 75% ethanol, 0.1% sodium hypochlorite, and 0.5% of hydrogen peroxide or on exposure to a temperature of 56°C for 30 min.[6,7]

Usually, the transmission of SARS-CoV-2 occurs by respiratory droplets. The threat is highest from asymptomatic people, who are accountable for up to 79% of infection as they remain active showing no symptoms. Until herd immunity is established either through infection or vaccination, testing remains the only mainstay as our primary defense.

The current diagnostic procedures are based on two principles either direct detection of the virus (or its part) or immunological testing which detects the consequences of infection in the host. These diagnostic aids can be valuable in conditions like symptomatic, at-risk pre-symptomatic individuals, confirmatory testing, differential diagnosis, testing of patients with previous exposure; surveillance at sites of previous/potential outbreaks, and treatment monitoring.

Currently available tests are technique sensitive, time-consuming, expensive, lack specificity, and require trained health care professionals. Salivary biomarkers can be extremely promising in both testing and monitoring patients in real-time which is exceedingly critical in this pandemic era when physicians and primary care providers need consistent diagnostic tools to prioritize patients' access to intensive care. Saliva allows for a fast, easy, affordable, and non-invasive collection of specimens that can be repeated multiple times. This review aims at analyzing the presently available literature regarding saliva and its role in COVID diagnosis and monitoring.

**Methods**

**Study design**

This review was planned following PRISMA criteria to evaluate the role of saliva as a dependable fluid in COVID diagnosis. The review included studies published till January 2021 of various types including case-control studies, cross-sectional, prospective studies, case reports, and reviews [Flowchart 1].

**Search approach**

The search was carried out on January 10, 2021, in the PubMed database, and keywords were chosen with MeSH terms. The MeSH terms included—saliva and COVID-19, saliva and SARS-CoV-2, saliva as a diagnostic tool, oral saliva and COVID, saliva and antibodies in SARS-CoV-2. The search approach did not impose language, year or publication type restrictions. The search strategy that was accepted is as follows:

**Selection principles**

Studies were considered to be eligible for inclusion if they accessed the data of saliva in diagnostic use or as the presence of a biomarker in salivary samples of COVID-19 positive patients. Studies were excluded if: 1. They were not original research. 2. Not peer-reviewed. 3. Unpublished conference abstracts. Authors jointly decided on inclusion and exclusion criteria and the reference list was made and analyzed. Subsequently, the reference list was checked manually to identify any articles that could have been lost.

**Study selection**

The search retrieved a total of 309 articles across the PubMed database [Flowchart 2]. After removal of the duplicates and evaluation of the abstracts and titles was carried out, concentrating on the diagnostic property of saliva and formation of antibodies. After the exclusion of 206 articles, 103 articles were reserved. Reviews and meta-analyses were excluded if there was inadequate data on diagnosis or use as a biomarker. This resulted in the exclusion of 68 articles and 30 articles were selected. Subsequently, three other articles were excluded as it was difficult to differentiate between sputum and deep throat salivary samples based on the method used in the study.

**Data retrieval**

Retrieval and reviewing of collected data for the year of publication, author, nature of the study, type of sample, kind of microbiological assay used, and significant deductions were assessed [Table 2]. Individual studies were comprehensively evaluated and critically analyzed by the authors separately for all the available pieces of evidence.

**Results**

**Study attributes**

All the selected studies were published before 2021, were written in the English language, and conducted in 11 countries: China, Japan, Iran, USA, Taiwan, Israel, Italy, Malaysia, Canada, Singapore, and India. The majority indicated the use of saliva as a diagnostic tool and compared it with the other frequently employed methods. No study was undertaken on neonate or pediatric patients. The sample size ranged from 1 to 564 with a total of 3544 for the review. The majority of the studies suggested the use of saliva in diagnosing the presence of SARS-CoV-2 infection or the presence of biomarkers against the viral activity.

**Overall view**

The most used method of testing the salivary sample is the reverse transcriptase polymerase chain reaction (RT-PCR). Other methods included reverse transcriptase direct polymerase
Integrated Results

As of January 10, 2021, a total of 27 studies mentioned the presence of SARS-CoV-2 in salivary samples. The method of salivary sample collection was mentioned by some authors but mostly, the general term saliva was used without detailing the technique. A comparison was made of studies where different salivary collection and testing methods were used for confirming the results. Studies that described the efficiency of the salivary sample and compared it to nasopharyngeal swabs (NPS) or oropharyngeal swabs were also scrutinized.

Synthesis of the results

The samples collected were either self-collected or collected by a healthcare worker. The salivary samples used were unstimulated saliva, sputum sample, deep throat sample, drooling saliva, oral swabs, and posterior oropharyngeal saliva. None of the studies compared each of these techniques to the other.

Results of review

As of now till January 20, 2021, there have been 94,963,847 confirmed cases of COVID-19, including 2,050,857 deaths, reported to World Health Organization (WHO). Chest computed tomography shows a pathognomic ground-glass appearance. The specimen is collected from the upper respiratory tract and hence NPS and oropharyngeal swab collections are considered to be a gold standard. Owing to its invasive nature, collecting the specimen requires close contact between the patients and the health care workers. Furthermore, in patients receiving anticoagulant therapy or having thrombocytopenia, it may be painful and may induce bleeding and hence in such conditions, nasopharyngeal/oropharyngeal sample collections are not desirable. These conditions support non-invasive collection methods, that is, by asking the patients to spit saliva in the sterile container and then check for the viral load.

Saliva: As a prompt promoter of COVID-19

As of now till January 20, 2021, there have been 94,963,847 confirmed cases of COVID-19, including 2,050,857 deaths, reported to World Health Organization (WHO). Chest computed tomography shows a pathognomic ground-glass appearance. The specimen is collected from the upper respiratory tract and hence NPS and oropharyngeal swab collections are considered to be a gold standard. Owing to its invasive nature, collecting the specimen requires close contact between the patients and the health care workers. Furthermore, in patients receiving anticoagulant therapy or having thrombocytopenia, it may be painful and may induce bleeding and hence in such conditions, nasopharyngeal/oropharyngeal sample collections are not desirable. These conditions support non-invasive collection methods, that is, by asking the patients to spit saliva in the sterile container and then check for the viral load.

Saliva: As a prompt promoter of COVID-19

As of January 10, 2021, a total of 27 studies mentioned the presence of SARS-CoV-2 in salivary samples. The method of salivary sample collection was mentioned by some authors but mostly, the general term saliva was used without detailing the technique. A comparison was made of studies where different salivary collection and testing methods were used for confirming the results. Studies that described the efficiency of the salivary sample and compared it to nasopharyngeal swabs (NPS) or oropharyngeal swabs were also scrutinized.

Synthesis of the results

The samples collected were either self-collected or collected by a healthcare worker. The salivary samples used were unstimulated saliva, sputum sample, deep throat sample, drooling saliva, oral swabs, and posterior oropharyngeal saliva. None of the studies compared each of these techniques to the other.

Results of review

As of now till January 20, 2021, there have been 94,963,847 confirmed cases of COVID-19, including 2,050,857 deaths, reported to World Health Organization (WHO). Chest computed tomography shows a pathognomic ground-glass appearance. The specimen is collected from the upper respiratory tract and hence NPS and oropharyngeal swab collections are considered to be a gold standard. Owing to its invasive nature, collecting the specimen requires close contact between the patients and the health care workers. Furthermore, in patients receiving anticoagulant therapy or having thrombocytopenia, it may be painful and may induce bleeding and hence in such conditions, nasopharyngeal/oropharyngeal sample collections are not desirable. These conditions support non-invasive collection methods, that is, by asking the patients to spit saliva in the sterile container and then check for the viral load.

Saliva: As a prompt promoter of COVID-19

As of January 10, 2021, a total of 27 studies mentioned the presence of SARS-CoV-2 in salivary samples. The method of salivary sample collection was mentioned by some authors but mostly, the general term saliva was used without detailing the technique. A comparison was made of studies where different salivary collection and testing methods were used for confirming the results. Studies that described the efficiency of the salivary sample and compared it to nasopharyngeal swabs (NPS) or oropharyngeal swabs were also scrutinized.

Synthesis of the results

The samples collected were either self-collected or collected by a healthcare worker. The salivary samples used were unstimulated saliva, sputum sample, deep throat sample, drooling saliva, oral swabs, and posterior oropharyngeal saliva. None of the studies compared each of these techniques to the other.

Results of review

As of now till January 20, 2021, there have been 94,963,847 confirmed cases of COVID-19, including 2,050,857 deaths, reported to World Health Organization (WHO). Chest computed tomography shows a pathognomic ground-glass appearance. The specimen is collected from the upper respiratory tract and hence NPS and oropharyngeal swab collections are considered to be a gold standard. Owing to its invasive nature, collecting the specimen requires close contact between the patients and the health care workers. Furthermore, in patients receiving anticoagulant therapy or having thrombocytopenia, it may be painful and may induce bleeding and hence in such conditions, nasopharyngeal/oropharyngeal sample collections are not desirable. These conditions support non-invasive collection methods, that is, by asking the patients to spit saliva in the sterile container and then check for the viral load.

Saliva: As a prompt promoter of COVID-19

As of now till January 20, 2021, there have been 94,963,847 confirmed cases of COVID-19, including 2,050,857 deaths, reported to World Health Organization (WHO). Chest computed tomography shows a pathognomic ground-glass appearance. The specimen is collected from the upper respiratory tract and hence NPS and oropharyngeal swab collections are considered to be a gold standard. Owing to its invasive nature, collecting the specimen requires close contact between the patients and the health care workers. Furthermore, in patients receiving anticoagulant therapy or having thrombocytopenia, it may be painful and may induce bleeding and hence in such conditions, nasopharyngeal/oropharyngeal sample collections are not desirable. These conditions support non-invasive collection methods, that is, by asking the patients to spit saliva in the sterile container and then check for the viral load.

Saliva: As a prompt promoter of COVID-19

As of now till January 20, 2021, there have been 94,963,847 confirmed cases of COVID-19, including 2,050,857 deaths, reported to World Health Organization (WHO). Chest computed tomography shows a pathognomic ground-glass appearance. The specimen is collected from the upper respiratory tract and hence NPS and oropharyngeal swab collections are considered to be a gold standard. Owing to its invasive nature, collecting the specimen requires close contact between the patients and the health care workers. Furthermore, in patients receiving anticoagulant therapy or having thrombocytopenia, it may be painful and may induce bleeding and hence in such conditions, nasopharyngeal/oropharyngeal sample collections are not desirable. These conditions support non-invasive collection methods, that is, by asking the patients to spit saliva in the sterile container and then check for the viral load.
The cause of infection is both the salivary gland and saliva. The expression of ACE-2 in minor salivary glands was higher than that in lungs (lung medium PTM: 1.010, minor salivary gland medium PTM: 2.013). Rate- up to 91.7% for salivary samples.

S487 T mutation adds a favourable interaction at the RBD-human ACE-2 interface. It increases viral binding to human ACE-2 and plays role in human-to-human transmission. It provides information to understand the genomic sequence in humans compared to bats. Close monitoring of patients is essential for early recognition of the emergence of novel mutations at 501 positions.

ACE-2 receptors are highly concentrated in lymphocytes of salivary glands, lungs, and digestive tract. Among 32 adjacent normal tissues in the oral cavity, 13 tissues are in the tongue, 2 at the base of the tongue, 3 on the floor of the mouth, and 14 tissues did have no definite site and were just put into the category of the oral cavity.

ACE-2 receptors are highly concentrated in salivary glands in young Asian females compared to males. When studied in mice, cytokine storm in SARS-CoV-2 severe symptom patients, showed a decline of ACE-2, which further harmed CD4+ T cells and Treg cells. Lower estrogen levels contributed to higher ACE-2 expression in Asian females than males. ACE-2 expression was induced by estrogen plus androgen block or even estrogen alone. The decline of sex hormones contributed to ACE-2 expression decrease with an increase in age.

ACE-2 receptors are concentrated in the salivary glands and the major symptoms were dry mouth and ambygeustia. Three positive cases were critically ill and on ventilator support, providing high potential (75%) for detection of 2019-nCoV in the saliva. The two major oral-related symptoms were dry mouth (46.3%) and ambygeustia (47.2%), were found in a high proportion in the COVID-19 patients.

ACE-2 was highly expressed in the testis, small intestine, and adipose tissue whereas, lower expression was seen in the spleen and blood. TMPRSS2 was highly expressed in the pituitary gland and prostate whereas lesser expressed in the spleen, heart, adipose tissue, and blood. ACE-2 and TMPRSS2 both are moderately expressed in oral mucosa and salivary glands and hence SARS-CoV-2 may be concentrated in salivary glands due to the presence of ACE-2 receptors with Pearson's correlation coefficient R=0.35, P=0.01, N=55 positive correlation.

Hyposalivation may be a risk factor for acute severe respiratory syndrome when studied on 323 individuals. Out of the 278 patients completing the study, the incidence of acute respiratory infection was 60.4%, while hyposalivation was present in 96 subjects (35.5%). Improvement in hyposalivation may improve the prevention possibility of acute respiratory infection.

Serial salivary samples exhibit a progressive decrease in SARS-CoV-2 titres on taking serial salivary samples. When tested with NPS and salivary samples, five earlier negative NPS were found positive on getting retested but no change in results with salivary samples was reported.

No decrease in SARS-CoV-2 titers of salivary samples. Saliva remains positive even after 25 days after the first symptom appears.

The efficacy of RT-LAMP was equal to that of RT-PCR after more than 40 min had passed. The Human pop7 gene was taken as a control. It showed an equal positive ratio for both salivary and NPS samples. The sensitivity of RT-LAMP is 97-100% after 30 min had passed to RT-PCR. Efficacy of both salivary and NPS samples was equal with 5/24 positive patients, that is, 20.34%.

### Table 2: Studies investigating the role of saliva in SARS-CoV-2 diagnosis

| Reference | Sample size | Sample type | Methods used | Inferences derived |
|-----------|-------------|-------------|--------------|--------------------|
| Xu J et al.[9] 2020 (China) | Not mentioned | Human organs | GTEEx portal | S487 T mutation adds a favourable interaction at the RBD-human ACE-2 interface. It increases viral binding to human ACE-2 and plays role in human-to-human transmission. It provides information to understand the genomic sequence in humans compared to bats. Close monitoring of patients is essential for early recognition of the emergence of novel mutations at 501 positions. |
| Wang W-K et al.[7] 2020 (Taiwan) | 17 | Saliva | RT-PCR | No decrease in SARS-CoV-2 titers of salivary samples. Saliva remains positive even after 25 days after the first symptom appears. |
| Ben-Assa N et al.[10] 2020 (Israel) | 182 | Throat Nasal swabs Self-collected saliva | RT-LAMP RT-PCR RT-PCR | The efficacy of RT-LAMP was equal to that of RT-PCR after more than 40 min had passed. The Human pop7 gene was taken as a control. It showed an equal positive ratio for both salivary and NPS samples. The sensitivity of RT-LAMP is 97-100% after 30 min had passed to RT-PCR. Efficacy of both salivary and NPS samples was equal with 5/24 positive patients, that is, 20.34%. |

**Contd...**
Saliva is a utility fluid that helps in measuring IgA against SARS-CoV-2 in the initial days of infection. Viral load is the same in nasopharyngeal (NPS) and saliva. Saliva is a better alternative that can be self-collected compared to health care workers. The overall acceptability of saliva and oropharyngeal samples was 84-86%. RT-PCR of saliva and oropharyngeal samples gave better results compared to nasopharyngeal sample. The sensitivity of Rapid Salivary testing is equal to that of RT-PCR which is 93%.

Inferences derived from Table 2:

| Reference | Sample size | Sample type | Methods used | Inferences derived |
|-----------|-------------|-------------|--------------|--------------------|
| Azzi L. et al. 2020 (Italy)²⁰⁴ | 140 | Saliva | RT-PCR | The sensitivity of Rapid Salivary testing is equal to that of RT-PCR which is 93%. |
| Nagura-Ikeda M et al. 2020 (Japan)²¹ | 103 | Saliva | LDT-RT-PCR; Cobas SARS-CoV-2 Direct RT-PCR; RT-LAMP; RAT | The sensitivity of LDT RT-PCR: 81.6%, Cobas SARS-CoV-2: 80.6%, direct RT-PCR: 76.7-78.6%, RT-LAMP: 50.5-70.9%, and RAT: 11.7%. |
| Lai CKC et al.²² 2020 (Hong Kong) | 563 | Deep throat sample Nasopharyngeal Sputum Dried blood spot | RT-PCR | The best way is sputum collection as the positive rates and viral RNA copies are higher in sputum and lower in deep throat saliva. The viral RNA copies in deep throat saliva were 3.54, in NPS is 4.63 and in sputum is 5.03. High viral RNA copies were found in the sputum sample compared to the deep throat salivary sample. Deep throat saliva showed a positive ratio of 68.7%, NPS 80.9%, and sputum 89.4%. A higher positive ratio was seen in sputum when tested with the RT-PCR method. |
| Valentine-Graves M et al. 2020 (USA)²³ | 153 | Saliva Oropharyngeal Dried blood clot | RT-PCR | Overall acceptability of saliva and oropharyngeal samples were 84-86% compared to a dried blood clot which was 90% |
| Procop GW et al. 2020 (USA)²⁴ | 224 | Saliva nasopharyngeal | RT-PCR | The midday or early morning sample efficiency of salivary samples remains the same. Total 38/216 samples were found positive with both nasopharyngeal and salivary sample with an exception of one sample, which was positive with the salivary sample and negative with a nasopharyngeal sample. |
| Rao M et al. 2020 (Malaysia)²⁵ | 217 | Saliva nasopharyngeal | RT-PCR | Saliva is a better alternative that can be self-collected compared to NPS swabs which can create a risk to the health care workers. In COVID-positive patients, nasopharyngeal sample 84/160 (52.5%), and salivary sample 149/160 (93.1%) gave positive results. |
| Iwasaki S et al. 2020 (Japan)²⁶ | 76 | Saliva nasopharyngeal | RT-PCR | In the initial days of infection, viral load is the same in NPS and salivary samples whereas it reduces gradually in later days in both. Of the 10 positive patients 2/10 (20%) with the nasopharyngeal sample, and 8/10 (80%) with the salivary sample gave positive results. |
| Kandel C et al. 2020 (Canada)²⁷ | 432 | Saliva | RT-PCR | Saliva is a noninvasively collected sample that can be taken to avoid risk to healthcare workers. The sample demonstrated a sensitivity of 0.91 and 0.93 for saliva and NPS. |
| Aita A et al. 2020 (Italy)²⁸ | 43 | Saliva | RT-PCR | Saliva is a utility fluid that helps in measuring IgA against SARS-CoV-2 positive patients where the ratio of positive and negative for saliva was the same. There was a difference of only one sample which tested positive with salivary sample and negative with NPS, that is, nasopharyngeal positive 7/43 (16.27%) and for salivary sample positive in 8/43 (18.60%). IgA antibody is found positive for 18/27 patients, that is, 66.67% of the cases. |
| Tajima Y et al. 2020 (Japan)²⁹ | 1 | Saliva | RT-PCR | 600 µL saliva was collected, the titers of antigen were found more in early morning samples compared to midday samples. |
| Azzi L et al. 2020 (Italy)³⁰ | 2 | Saliva Nasopharyngeal | RT-PCR | Salivary samples gave better results compared to nasopharyngeal samples on the 26th day. RT-PCR of the salivary sample was positive and the nasopharyngeal sample was negative initially, which after 2 days gave the same results. |
| Tan SY et al. 2020 (Singapore)³¹ | 500 | Saliva | RT-PCR | Self-swab or saliva has a lower efficiency than the health care workers but the combination of self-swab and saliva was equivalent to health care worker sample. Salivary sample: 74.3%, self-swab: 75.1%, health care worker: 82.8%, and saliva+self-swab: 86.5%, and for self-collected to health care worker samples, self-collected sample was 8.5% less than other samples and for saliva was 9.5%. |
| Varadacharya A et al. 2020 (USA)³² | 38 | Saliva | RT-PCR | IgA in saliva acts as a biomarker to identify patients at increased risk for clinical deterioration of COVID-19 symptoms. IgA antibodies were formed in the salivary samples where 35/38 patients had IgA antibodies (92.15%). |
| Desai S et al. 2020 (India)³³ | 201 | Saliva | Raman spectroscopy | The sensitivity of viral SARS-CoV-2 RNA was 106-1011 viral RNA copies/mL in saliva which can be detected by this method, and further, follow-up tests need to be performed to confirm the positivity. |

Contd...
Transmission through salivary droplets can occur when a person sneezes, coughs, breathes. Coughing can generate approximately 3000 salivary droplets which is equivalent to a 5-min talk whereas sneezing produces around 40,000 droplets which can cover several meters in the air.\cite{41,42}

A recent study reported that whenever a healthy person comes in contact with the infected one, the smaller infectious droplets travel a distance and can enter the mouth, eyes, or are inhaled into the lungs. This can be minimized to a degree by wearing a surgical mask and protective eyewear or face shield.\cite{13}

### Salivary glands

Early target cell for SARS-CoV-2 includes ACE-2 positive cells/keratin epithelial cells.\cite{54} In the early phase of infection, ACE-2 gene receptors are more frequently found in the salivary gland in comparison to the lungs. Lung medium post-translational modification (PTM [transcripts per kilobase of exon model per Million mapped]) is 1.010 whereas the minor salivary gland medium PTM is 2.013, which suggests salivary glands are a target for COVID-19. SARS-CoV-2 RNA is detected first in saliva even before the lung lesions explaining its presence in asymptomatic infections in saliva. The salivary gland could probably be a major source of virus in saliva and its infection rate can reach up to 91.7%.\cite{97} Saliva could be a substrate for viral multiplication explaining its high salivary transferability in asymptomatic patients.\cite{98} Thus salivary glands can be a potential source for transmission which should not be neglected.\cite{99}

ACE-2 receptors act as binding receptors of the SARS-CoV-2 virus:

The potential role of epithelial cells of the oral cavity and salivary glands in the expression of ACE-2 receptors was been analyzed by many authors. Hou Xu et al.\cite{11} studied the single-cell transcriptase analysis of normal oral mucosal biopsy expression of ACE-2 receptors and reported tongue had the maximum expression sites of 13 followed by the base of the tongue, the floor of the mouth, and oral cavity. High titers of the virus in saliva collected from salivary gland duct with high expression of ACE-2 receptors in a severely ill patient have been confirmed.\cite{12} In a study carried out at the beginning of the Coronavirus outbreak in China, a close relationship between the genome of rats, that is, RatG13, and humans on ACE-2 receptor was reported, and it was found to be its principal receptor.\cite{44} A high titer of the virus has been seen in saliva collected from the opening of salivary glands duct in severely ill patients.\cite{13} Furthermore, the submandibular gland showed still higher titers in comparison to the parotid gland.\cite{14}

### Hyposalivation as an early symptom

According to Iwabuchi et al.,\cite{13} hyposalivation could lead to severe acute respiratory infection attributed mainly to two reasons: (a) The mucosal surface of the oral cavity on reduced salivary secretion gets dry and enhances the adhesion and cohesion of the viruses. (b) This salivary reduction may also affect the secretion of antimicrobial proteins and peptides. Farshidfar N et al.\cite{45} hypothesized that hyposalivation may expose patients to a high risk of getting infected.

### Current diagnostic criteria for COVID-19 infection

According to WHO 2020 recommendation two samples one from the upper respiratory tract, that is, the NSP and oropharyngeal swab, and the second from the lower respiratory tract specimen, that is, sputum or endotracheal aspirate should be taken. The reason is, upper respiratory tract specimens may fail to detect early viral infections.\cite{96}

Saliva as a diagnostic agent has the advantages of being non-invasive, easy to gain, low cost, healthier to use than serum sampling. Furthermore, saliva samples do not clot which is an added benefit.\cite{47} Salivary sample collection can be performed either by salivary swabs, coughing out in a sterile container, or by salivary glands secretion collection by segregator cups. For early diagnosis, a sample from the lower respiratory tract or deep throat is needed.

Contradictory results were found in 12 severely ill patients, where a progressively decrease in SARS-CoV-2 titers was noted.\cite{10} Contrasting to this study, Wang W-K et al.\cite{17} reported no decrease in SARS-CoV-2 titers with time. Even after 25 days after the appearance of the first symptom, samples remained positive and titer remained high even after recovery.

Ben-Assa N et al.\cite{18} [Table 3] compared the sensitivity of RT-PCR to RT-LAMP where the human pop7 gene was taken as control and reported the effectiveness to be the same for both the techniques. The efficacy of RT-LAMP was similar after 40 min

### Table 2: Contd...

| Reference               | Sample size | Sample type | Methods used                  | Inferences derived                                                                 |
|-------------------------|-------------|-------------|-------------------------------|-----------------------------------------------------------------------------------|
| Samavati A et al. 2020 (Malaysia)\cite{47} | 06          | Saliva      | AU/FBG sensor probe was used with GO decorated to detect viral RNA and further tested by RT-PCR method | Wavelength increases with an increase in time and the sensitivity increases. This helps in accurate, easy, and remote sensing of COVID-19 patients. 1.6×103 copies/mL after 10 seconds by RT-PCR by QI Aamp kit tested for salivary samples. |

**PTM:** transcripts per kilobase of exon model per Million mapped reads; **RT-LAMP:** Reverse transcribed colorimetric loop-mediated isothermal amplification; **RT-PCR:** Reverse transcription-polymerase chain reaction; **SARS-CoV-2:** Severe Acute Respiratory Syndrome Coronavirus 2; 2019-nCoV: 2019 novel coronavirus; **RBD:** receptor-binding domain; **CD4+T cells:** cluster of differentiation 4+T helper cells; **RAT:** Rapid Antigen Test; **NPS:** Nasopharyngeal Swab; **Ig:** Immunoglobulins; **AU/FBG:** Fibre Bragg grating; **GO:** Graphene oxide; **HF:** Hydrogen fluoride; **ACE-2:** Angiotensin-converting enzyme 2; **TMPRSS2:** transmembrane serine proteases 2; **GTEx:** Genotype-Tissue Expression; **LDT:** Reverse transcription Polymerase Chain Reaction; **FANTOM5:** FANTOM 5 project; **CAGE:** Cap Analysis of Gene Expression
and there was a decrease in false-negative results over time. In another study, the sensitivity of RT-LAMP was found to be 97-100% after 30 min.[19]

Comparison of RT-PCR test to rapid salivary test and RT-LAMP test

The sensitivity of the rapid salivary test was found to be similar to that of RT-PCR which was 93% in a study performed on 140 samples.[24] In another study on 103 positive samples of asymptomatic as well as symptomatic patients the sensitivity of the various tests were found to be LDT RT-PCR-81.6%, Cobas SARS-CoV-2-80.6%, direct RT-PCR-76.7–78.6%, RT-LAMP-50.5–70.9%, and Rat-11.7%.[21] The best mode of sample collection is sputum because the viral RNA copies are higher in sputum and lower in deep throat saliva.[22] [Table 4]. The overall acceptability of saliva and oropharyngeal samples were 84–86% compared to a dried blood clot which was 90%.[23]

The time of sample collection was compared in multiple studies but contradictory results were reported [Table 5]. Early morning samples were reported to have high viral titers in one study whereas another found that the efficiency remained the same even in the midday sample.[16,24,25] Tajima Y et al.[26] reported a minimum quantity of 600 µL saliva gave accurate results but found higher viral titers in the early morning samples compared to midday. A similar initial viral load was recorded in both NPS and salivary samples although it reduced gradually in later days.[27] Contradictory to this Wyllie et al.[9] stated, there may be changes in the viral titer in NPS but no change was found in salivary samples. Kandel C et al.[28] emphasized that viscosity and amount of saliva also play a critical role in testing.

Two case studies concluded that although RT-PCR of NPS is a gold standard, salivary samples too gave promising results.[29] [Table 6]

Table 3: Comparison of RT-Lamp to gold-standard RT-PCR in SARS-CoV-2 testing

| Author            | Sample taken                  | Salivary sample | RT-PCR                      | RT-LAMP                      | Control gene         | Time elapsed |
|-------------------|-------------------------------|-----------------|------------------------------|------------------------------|----------------------|--------------|
| Ben-Assa N et al.[35] 2020 | -Throat                        | Case-1          | Positive-27                 | Positive-27                 | Human pop7 gene      | After 40 min |
|                    | -Nasal swabs                  | Total-99        | Negative-72                 | Negative-72                 |                      |              |
|                    | -Self-collected saliva        | Case-2          | Positive-52                 | Positive-52                 |                      |              |
|                    |                               | Total-83        | Negative-31                 | Negative-31                 |                      |              |
| Wei S et al.[36] in 2020 | Saliva                        | Total-24        | Positive-5                  | Positive-5                  | Not mentioned        | After 30 min |
|                    |                               |                 | Negative-19                 | Negative-19                 |                      |              |

SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2; RT-LAMP: Reverse transcribed Colorimetric loop-mediated isothermal amplification; RT-PCR: Reverse transcription Polymerase Chain Reaction

Table 4: Comparison of various sample collection techniques with RT-PCR testing

| Author         | Location   | Total patients | Deep throat saliva samples that is, oropharyngeal | Nasopharyngeal swabs | Sputum | Dried blood spot | Positive rates by RT-PCR | Viral RNA copies mean log copy/mL |
|----------------|------------|----------------|-----------------------------------------------|----------------------|--------|-----------------|--------------------------|----------------------------------|
| Lai CKC et al. 2020[22] | Hongkong   | 563            | 150                                           | 309                  | 104    | Not mentioned   | Deep throat Saliva-68.7% | NPS-80.9% Sputum-89.4% |
|                 |            |                |                                               |                      |        |                 | Deep throat Saliva-3.54 | NPS-4.63 Sputum-5.03 |

RT-PCR: Reverse transcription Polymerase Chain Reaction, NPS: Nasopharyngeal swabs

Table 5: Comparative studies to relate the efficacy of salivary samples to nasopharyngeal samples

| Author          | Samples                                           | Median age | Median days | Nasopharyngeal swab | Salivary samples | Comparison          | Efficiency  |
|-----------------|---------------------------------------------------|------------|-------------|---------------------|-----------------|---------------------|-------------|
| Procop GW et al. 2020[24] | Total-224 (8 - excluded, 7-indeterminant) Left-216 | Not mentioned | Not mentioned | Positive-38         | Positive-38     | NPS sample negative-1 | Not mentioned |
| Rao M et al. 2020[25]       | Total-217 positive males admitted 8-10 days before Total positive-160 | Not mentioned | Not mentioned | Positive-84/160     | Positive-149/160 | 84 samples were positive for NPS and 149 for salivary samples | Saliva-93.1% NPS-52.9% |
| Iwasaki S et al. 2020[27]   | Total-76 (positive-10, suspicious-66)            | 69 years   | 9 days      | Positive-2/10       | Positive-8/10   | Not mentioned        | Not mentioned |
| Kandel C et al. 2020[28]     | Total- 432, Reported in the study - 236         | 42 years   | 4 days      | NPS - 4 positive    | Saliva - 7      | Not mentioned        | Saliva- 91%   |
| Wylie et al. 2020[30]       | 1-121 samples of all participants 2-76 samples of paired NPS and saliva samples) | 1-61 years | 2-59 years  | NPS samples- 22     | Saliva samples-12 | NPS-5 tested negative initially later retesting-found positive. Salivary samples had no changes | Not mentioned |
| Aita A et al. 2020[31]      | Total- 43                                        | Not mentioned | Not mentioned | Positive-7         | Positive-7      | NPS sample-1 positive, NPS-1 negative | Not mentioned |

NPS: Nasopharyngeal swabs
Comparison of self-collected saliva to sample collected by health care worker

Efficacy of self-collected saliva in comparison to that taken in presence of health care workers have shown similar results.[16,23,34] A study carried out on 500 patients (400 were positive) with and without symptoms, the efficiency of saliva was reported to be with 74.3%, self-swab was 75.1% whereas with health care workers was 82.8%, and with self-swab was 86.5%. It concluded that the self-swab or saliva collection method had lower efficiency than the sample collected by health care workers but the combination of self-swab and saliva gave better results.[31]

Saliva: As a defense element

In agreement with previous studies, Farshidfar N et al.[49] reconfirmed that saliva contains Cystatin type II which possesses antiviral activity. Cystatins interfere with viral replication and also have antiviral effects as found previously against the herpes virus. Magister and Kos also claimed that Cystatin D takes part in inhibiting the replication of Coronavirus and has an antiviral protective role. Furthermore, salivary microvesicles present in saliva contain at least 20 types of microRNAs that restrict the replication of viruses.[49]

Multiple studies have claimed that increase IgA levels and serological free light chains of immunoglobulins in saliva act as a biomarker to identify patients at increased risk for clinical deterioration of COVID-19 symptoms.[15-34] [Table 7] Saliva can be a utility fluid that can measure IgA levels in positive patients.[28] Samavati A et al.[33] [Table 8] utilized AU/FBG sensor probe for viral RNA isolation and RT-PCR testing. Wavelength increased with time and the sensitivity improved correspondingly and this helps in accurate, easy, and remote sensing of COVID-19 patients. Newer detection methods based on the molecular analysis of facile detection of the viruses using DNA stabilized nanoclusters are also showing promising results.[40]

Interpretation of the review

This pandemic has highlighted the need to create awareness among dentists as they are high-risk professionals and at the maximum risk of acquiring the infection. It is equally essential for them to continually update themselves for spreading patient and community awareness regarding coronavirus. They need to remain abreast with the latest advancements in the field of isolation, early diagnosis, and sample collection methods and can play a pivotal role in saving lives.

It has become extremely essential to bring out the best and easiest possible way of testing which is accurate and dependable. India being the second-most populous country

| Table 6: Comparative studies of Corona positive patients with comorbidities |
|---------------------------------|-----------|----------------|----------------|----------------|
| **Author**                     | **Region** | **Age** | **Days of collecting sample after being tested positive** | **Comorbidity/other symptoms** |
| Tajima Y et al. 2020[24]   | Japan     | 71     | 37                     | Allergic Rhinitis |
| Azzi I. et al. 2020[23]     | Italy     | 71     | 10                     | Lipidaemia, obesity, hypertrophy, fever, dyspnoea |
| Azzi I. et al. in 2021[29]  | Italy     | 64     | 26                     | Hypertension, Dyspnoea, cough, fever |

| **Sampling method** | Saliva |
|---------------------|--------|
| RT-PCR of the salivary samples - positive, NPS - negative |
| RT-PCR of saliva sample - positive, NPS - negative |

| Table 7: Antibodies formation against SARS-CoV-2 virus |
|---------------------------------|-------------|----------------|----------------|----------------|
| **Author**                     | **Median days** | **Time required** | **Salivary samples** | **RT-PCR positive** | **IgA antibody** | **Serum IgA** | **Serum IgG** | **Serum IgM** |
| Varadacharya A et al. 2020[32] | 61          | 5-10 min        | 38                     | 38               | Positive-35/38   | Not mentioned | Not mentioned | Not mentioned |
| Aita A et al. 2020[38]        | Not mentioned | Not mentioned   | 27                     | 27               | Negative-3/38    | Positive-18/27 | Positive-16   | Positive-9/16 |

| **Ig; Immunoglobulin; RT-PCR: Reverse transcription Polymerase Chain Reaction** |

| Table 8: Additional methods of testing salivary samples for SARS-CoV-2 |
|---------------------------------|-------------|----------------|----------------|----------------|
| **Author**                     | **Method** | **Total patients** | **Median age** | **Sample taken** | **Positive/Negative** | **Storage temperature** | **Isolation of virus** | **Detection consistency and method** |
| Desai S et al. in 2020[35]    | Raman spectroscopy | 201              |                | 1 mL of unstimulated Saliva | Lentiviral RNA test Positive-54 | 4°C to (-20) °C | 7.05 × 10<sup>5</sup> TU/mL |
| Samavati A et al. in 2020[33] | AU/FBG sensor probe with GO decorated | Total-6 | 58.5 | Saliva | 30% HF solution at 15°C | QI Amp viral RNA mini kit | 1.6 × 10<sup>4</sup> copies/mL after 10 seconds by RT-PCR |

| **AU/FBG: Fiber Bragg grating probe; GO: Graphene oxide; RT-PCR: Reverse transcription Polymerase Chain Reaction; HF: Hydrogen Fluoride; QI Amp: QI Amp Viral RNA kit** |

Journal of Family Medicine and Primary Care 2299

Volume 11 : Issue 6 : June 2022
was hit hard twice by the infection and needs a testing method suitable for all individuals with the least possible resources. Research outcomes have indicated that due to its novelty, as well as the large spectrum of potential applications saliva could be a reliable and financially viable option in both testing viral titers and marking for bio analytes due to its propitious specificity and sensitivity results reported in most of the studies. Furthermore, hyposalivation leading to burning and redness of mucosa is also one of the common symptoms encountered among the patients who tested positive which could help in the early detection too.

However, the inferences drawn from many of these studies should be interpreted with caution due to small sample sizes, inadequate detailing on the sample handling, laboratory processing, and rush in Corona-related publication. Scientific research with larger sample sizes, in diverse populations and age groups, at different phases of disease progression of COVID are essential to reach any conclusion regarding its multi-facet use in the future.

**Conclusion**

Saliva not only transmits the virus but also the presence of various biomarkers in it makes it the body’s first line of defense against the virus. Saliva is a self-collecting fluid that can be collected and transferred to the laboratory where it can be tested non-invasively and especially easily accepted by small children/elderly patients and differently-abled people where nasopharyngeal sample collection is not acceptable.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Geneva: World Health Organization 2020. Available from: https://www.who.int/news-room/feature-stories/detail/who-china-joint-mission-on-coronavirus-disease-2019-(covid-19).pdf. [Last accessed on 2020 Feb 16].
2. Dar Odeh N, Babkair H, Abu-Hammad S, Borzangy S, Abu-Hammad A, Abu-Hammad O. COVID-19: Present and future challenges for dental practice. Int J Environ Res Public Health 2020;17:e3151.
3. Fan Y, Zhao K, Shi Z-L, Zhou P. Bat Coronaviruses in China. Viruses 2019;11:e210.
4. Van DN, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020;382:1564-7.
5. Chin AWH, Chu JTS, Perera MRA, Hui KPY, Yen H-L, Chan MCW, et al. Stability of SARS-CoV-2 in different environmental conditions. Lancet Microbe 2020;1:e10.
6. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect 2020;104:246-51.
7. World Health Organisation. Modes of transmission of virus causing COVID-19: Implications for IPC precaution recommendation. Available from: https://www.who.int/news-room/commentaries/detail/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations. [Last accessed on 2020 Mar 29].
8. To KK-W, Tsang OT-Y, Yip CC-Y, Chan K-H, Wu T-C, Chan JM-C, et al. Consistent detection of 2019 Novel Coronavirus in saliva. Clin Infect Dis 2020;71:841-3.
9. Xu J, Li Y, Gan F, Du Y, Yao Y. Salivary glands: Potential reservoirs for COVID-19 asymptomatic infection. J Dent Res 2020;99:980.
10. Yan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS coronavirus. J Virol 2020;17:e00127-20.
11. Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci 2020;12:8.
12. Chen J, Jiang Q, Xia X, Liu K, Yu Z, Tao W, et al. Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation. Aging Cell 2020;19:e13168.
13. Chen L, Zhao J, Peng J, Li X, Deng X, Geng Z, et al. Detection of 2019-nCoV in Saliva and characterization of oral symptoms in COVID-19 patients. Available from: https://papers.ssrn.com/abstract=3356665. [Last accessed on 2020 Mar 14].
14. Song J, Li Y, Huang X, Chen Z, Li Y, Liu C, et al. Systematic analysis of ACE2 and TMPRSS2 expression in salivary glands reveals underlying transmission mechanism caused by SARS-CoV-2. J Med Virol 2020;92:2556-66.
15. Ibawuchi H, Fujibayashi T, Yamane G-Y, Imai H, Nakao H. Relationship between hyposalivation and acute respiratory infection in dental outpatients. Gerontol 2012;58:205-11.
16. Wylie AL, Fournier J, Casanovas-Massana A. Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs. N Engl J Med 2020;383:1283-6.
17. Wang W-K, Chen S-Y, Liu I-J, Chen Y-C, Chen H-L, Yang C-F, et al. Detection of SARS-associated coronavirus in throat wash and saliva in early diagnosis. Emerg Infect Dis 2004;10:1213-9.
18. Ben-Assa N, Naddafi R, Gefen T, Capucha T, Hajjo H, Mandelbaum N, et al. Direct on-the-spot detection of SARS-CoV-2 in patients. Exp Biol Med 2020;245:1187-93.
19. Wei S, Kohl E, Djandji A, Morgan S, Whittier S, Mansukhani M, et al. Field-deployable, rapid diagnostic testing of saliva samples for SARS-CoV-2. Available from: http://dx.doi.org/10.1101/2020.06.13.21029441. [Last accessed on 2020 Jun 16].
20. Azzi L, Baj A, Alberio T, Lualdi M, Veronesi G, Carcano G, et al. Rapid saliva test suitable for a mass screening program to detect SARS-CoV-2: A diagnostic accuracy study. J Infect 2020;81:247-51.
21. Nagura-Ikeda M, Imai K, Tabata S, Miyoshi K, Murahara N, Mizuno T, et al. Clinical evaluation of self-collected saliva by Quantitative Reverse Transcription-PCR (RT-qPCR), direct RT-qPCR, reverse transcription-loop-mediated isothermal amplification, and a rapid antigen test to diagnose COVID-19. J Clin Microbiol 2020;58:e01438-20.
22. Lai CKC, Chen Z, Liu G, Ling L, Li T, Wongs W, et al. Prospective study comparing deep throat saliva with other respiratory tract specimens in the diagnosis of novel coronavirus disease. J Infect Dis 2020;222:1612-9.

23. Valentine-Graves M, Hall E, Guest JL, Adam E, Valencia R, Shinn K, et al. At-home collection of saliva, oropharyngeal swabs and dried blood spots for SARS-CoV-2 diagnosis and serology: Post-collection acceptability of specimen collection process and patient confidence in specimens. PLoS One 2020;15:e0236775.

24. Procop GW, Shrestha NK, Vogel S, Van Sickel K, Harrington S, Rhoads DD, et al. A direct comparison of enhanced saliva to nasopharyngeal swab for the detection of SARS-CoV-2 in symptomatic patients. J Clin Microbiol 2020;58:e01946-20.

25. Rao M, Rashid FA, Sabri FS, Jamil NN, Hashim R, et al. Comparing nasopharyngeal swab and early morning saliva for the identification of SARS-CoV-2. Clin Infect Dis 2020;72:352-6.

26. Tajima Y, Suda Y, Yano K. A case report of SARS-CoV-2 confirmed in saliva specimens up to 37 days after onset: Proposal of saliva specimens for COVID-19 diagnosis and virus monitoring. J Infect Chemother 2020;26:1086-9.

27. Iwasaki S, Fujisawa S, Nakakubo S, Kamada K, Yamashita Y, Fukumoto T, et al. Comparison of SARS-CoV-2 detection in nasopharyngeal swab and saliva. J Infect 2020;81:e145-7.

28. Kandel C, Zheng J, McCready J, Racher H, Desaulnier M, et al. Detection of SARS-CoV-2 from saliva as compared to nasopharyngeal swabs in outpatients. Viruses 2020;12:1314.

29. Azzi L, Carcano G, Dalla Gasperina D, Sessa F, Maurino V, Baj A. Two cases of COVID-19 with positive salivary and negative pharyngeal or respiratory swabs at hospital discharge: A rising concern. Oral Dis 2021;27:707-9.

30. Aita A, Basso D, Cattelan AM, Fioretto P, Navaglia F, Barbaro F, et al. SARS-CoV-2 identification and IgA antibodies in saliva: One sample two tests approach for diagnosis. Clin Chim Acta 2020;510:127655.

31. Tan SY, Tey HL, Lim ETH, Toh ST, Chan YH, Tan PT, et al. The accuracy of healthcare worker versus self-collected (2-in-1) Oropharyngeal and Bilateral Mid-Turbinate (OPMT) swabs and saliva samples for SARS-CoV-2. PLoS One 2020;15:e0244417.

32. Varadhachary A, Chatterjee D, Garza J, Patrick Garr R, Foley C, Letkeman A, et al. Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19. MedRxiv 2020. doi:10.1101/2020.08.07.20170258.

33. Samavat A, Samavati Z, Velasjerdi M, Fauzi Ismail A, Othman MHD, Eisaabadi BG, et al. Sustainable and fast saliva-based COVID-19 virus diagnosis kit using a novel GO-decorated Au/FBG sensor. Chem Eng J 2021;420:127655.

34. Napodano C, Callà C, Fiorita A, Marino M, Taddei E, Di Cesare T, et al. Salivary biomarkers in COVID-19 patients: Towards a wide-scale test for monitoring disease activity. J Pers Med 2021;11:385.

35. Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20.

36. World Health Organisation. Coronavirus disease (COVID-19) dashboard. COVID-19 Special Issue 10. Available from: https://covid19.who.int/. [Last accessed on 2020 Nov 03].

37. Zhang C-Z, Cheng X-Q, Li J-Y, Zhang P, Yi P, Xu X, et al. Saliva in the diagnosis of COVID-19. Int J Oral Sci 2016;8:133-7.

38. Li Y, Ren B, Peng X, Hu T, Li J, Gong T, et al. Saliva is a non-negligible factor in the spread of COVID-19. Mol Oral Microbiol 2020;35:141-5.

39. Xu R, Cui B, Duan X, Zhang P, Zhou X, Yuan Q. Saliva: Potential diagnostic value and transmission of 2019-nCoV. Int J Oral Sci 2020;12:e11.

40. Fennelly KP, Martyn JW, Fulton KE, Orme IM, Cave DM, Heffets LB. Cough-generated aerosols of Mycobacterium tuberculosis: A new method to study infectiousness. Am J Respir Crit Care Med 2004;169:604-9.

41. Kohn WG, Collins AS, Cleveland JL, Harte JA, Eklund KJ, Malvitz DM, et al. Guidelines for infection control in dental health-care settings-2003. MMWR Recomm Rep 2003;52:1-61.

42. Cole EC, Cook CE. Characterization of infectious aerosols in health care facilities: An aid to effective engineering controls and preventive strategies. Am J Infect Control 1998;26:453-64.

43. Baghizadeh FM. What dentists need to know about COVID-19. Oral Oncol 2020;105:e104741.

44. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270-3.

45. Farshidfar N, Hamedani S. Hyposalivation as a potential risk for SARS-CoV-2 infection: Inhibitory role of saliva. Oral Dis 2020;10:1111.

46. Han P, Ivanovski S. Saliva-friend and foe in the COVID-19 outbreak. Diagnostics 2020;10:290.

47. Sri Santosh T, Parmar R, Anand H, Srikanth K, Saritha M. A review of salivary diagnostics and its potential implication in detection of Covid-19. Cureus 2021;13:e7708.

48. Ku CW, Shivani D, Kwan JQ, Loy SL, Erwin C, Ko KK, et al. Validation of self-collected buccal swab and saliva as a diagnostic tool for COVID-19. Int J Infect Dis 2021;104:255-61.

49. Desai S, Mishra SV, Joshi A, Sarkar D, Hole A, Mishra R, et al. Raman spectroscopy-based detection of RNA viruses in saliva: A preliminary report. J Biophotonics. 2020;13:e202000189.